Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Acrivon Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$1.48

+0.06 (+4.17%)

C 41Pipeline Score Overvalued Pharma · Clinical
Market Cap
67.20 M
EPS
-2.00
P/E Ratio
-0.78 $
Value Trade
467.53 K
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • R&D Expenses

    15.17 M

  • Operating CF

    -20.54 M

  • Total Assets

    107.83 M

  • Total Liabilities

    12.32 M

  • Equity

    95.52 M

  • D/E Ratio

    12,345

-7.89 %
Week
-2.23 %
1 Month
11.46 %
3 Month
-23.91 %
6 Month
-86.89 %
5 Year
-86.89 %
All Time
Cash Data
Stable

  • Cash Position

    97.74 M

  • Monthly Burn

    6.85 M

  • Runway

    13.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
297.32 K
52 Week Range
1.15 - 3.56
% held by Insiders
23.47 %
% held by Institutions
42.69 %
Enterprise Value
-28.12 M
Total Shares
31.56 M
Short %
19.47 %
Float Shares
14.39 M
Company Description
HQ: 480 ARSENAL WAY, SUITE 100, WA...
Founded:2018
Employees:76
https://www.acrivon.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C41
Pipeline Score
$37M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.6x
rNPV / MCap
Top 56%
Micro Cap
(rank 399 of 905)
Percentile Rank
Acrivon Therapeutics, Inc. carries a moderate pipeline score (41/100), with $963M risk-adjusted pipeline value, led by ACR-2316 in Specific Advanced Solid Tumors (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ACR-2316
Small molecule		Specific Advanced Solid TumorsPhase 1NCT0666714110% $568M RECRUITING 100 AVERAGE C (46) Dec 12, 2026MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ACRV
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ACRV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACRV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACRV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ACRV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ACRV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Acrivon Therapeutics, Inc. (ACRV) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ACRV ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Endometrial Cancer #15 of 48 PHASE 2 ACR-368 + Gemcitabine
MRK AZN GILD
$31.09B 0.76 FOLLOWER